|
|
 |
| |
Back to MAAUA Scientific Program
Percent Positive Prostate Biopsy Cores and Biochemical Outcome in Patients with Low-Risk Prostate Cancer Treated with Brachytherapy or Three Dimensional Conformal External Beam Radiotherapy
Mark L. Pe1, Edouard J. Trabulsi1, Christopher Yingling*1, Ramalinga Kedika*2, Adam P. Dicker2, Leonard G. Gomella1, Richard K. Valicenti2
1Thomas Jefferson University, Department of Urology, Philadelphia, PA;2Thomas Jefferson University, Department of Radiation Oncology, Philadelphia, PA
Introduction: To investigate the significance of percent positive biopsy cores (PPBC) in predicting biochemical outcome in patients with low-risk prostate cancer receiving either brachytherapy or three-dimensional conformal external beam radiotherapy (3D-CRT).
Methods: We retrospectively reviewed 390 low-risk prostate cancer patients (clinical stage T1/T2a, Gleason ≤ 6, and pre-treatment PSA ≤ 10) who underwent brachytherapy or 3D-CRT between 1993 and 2006. 197 patients underwent 3D-CRT and 193 underwent brachytherapy. Patients were stratified according to treatment modality and ≤33%, 33-50%, >50% PPBC. Biochemical failure was defined by the 2006 RTOG-ASTRO Phoenix Consensus Conference definition (rise by ≥ 2 ng/mL above the nadir PSA).
Results: Preliminary data reveal: median ages and PSA for the 3D-CRT and brachytherapy cohorts were 70 (range 49-83) and 65 (range 42-98), and 6.5 (range 0.6-9.9) and 5.8 (range 0.8-9.8), respectively. The median follow-up in the 3D-CRT and brachytherapy groups was 52 months (range 1-148) and 36 months (range 1-114). The number of patients who had PPBC ≤33%, 33-50%, and >50% in the 3D-CRT and brachytherapy populations were 145 (75.1%), 29 (15%), and 19 (9.8%), and 140 (72.5%), 32 (16.6%), and 16 (8.3%), respectively. No significant differences in age, clinical stage, Gleason score, or PPBC between the two cohorts were seen. When freedom from biochemical failure was stratified for PPBC, no significant difference was seen for either treatment modality.
Conclusions: In patients with low-risk prostate cancer, brachytherapy and external beam radiotherapy remain excellent treatment choices regardless of tumor volume, estimated by PPBC.
Back to MAAUA Scientific Program
|
|
| |
|
|
| |
|
|
|
|
